Clinical Trial Update: Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating efficacy and safety of Evoglitin in patients with type 2 diabetes and non-alcoholic fatty liver disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• Evoglitin

Snippet

Sponsor: Dong-A ST Co., Ltd. | Conditions: Type2 Diabetes, Non-Alcoholic Fatty Liver Disease | Phase 4 | Status: COMPLETED